ReviewNature reviews. Nephrology2015
Renal effects of targeted anticancer therapies.
Review in Nature reviews. Nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- Association between increased proteinuria induced by Bevacizumab, Ramucirumab, and Aflibercept and the risk of renal impairment and failure: a systematic review and meta-analysis.International journal of clinical oncology · 2025Pooled it
- Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.Clinical genitourinary cancer · 2016Trial
- Elucidating Therapeutic Targets in Hereditary Multicentric Carpotarsal Osteolysis FSGS.Journal of the American Society of Nephrology : JASN · 2026Article
- The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup.Nature reviews. Nephrology · 2026Review
- Article
- Clinical management of cancer after kidney transplantation.Frontiers in immunology · 2026Review
- BCR-ABL tyrosine kinase inhibitors associated acute kidney injury: a pharmacovigilance study based on the FAERS database with a case report.BMC nephrology · 2025Article
- Prognostic Impact of Glomerular Filtration Rate Decline on Survival Outcomes in Metastatic Renal Cell Carcinoma Treated with Targeted Therapy.Medicina (Kaunas, Lithuania) · 2025Article
- Therapeutic potential of betaine and its derivatives in cancer treatment: a comprehensive review.RSC advances · 2025Review
- Hypertension in Childhood Cancer Survivors: Causes, Screening, and Management.Current hypertension reports · 2025Review
- Artificial Intelligence and Machine Learning Models for Predicting Drug-Induced Kidney Injury in Small Molecules.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Successful post-incomplete resection management of gastrointestinal stromal tumor using imatinib based on adenosine triphosphate-based tumor sensitivity assay in a dog.The Canadian veterinary journal = La revue veterinaire canadienne · 2024Article
- The Influence of Betulin Derivatives EB5 and ECH147 on the Expression of Selected TGFβ Superfamily Genes,Current issues in molecular biology · 2023Article
- Development and Validation of a Prediction Model for Kidney Failure in Long-Term Survivors of Childhood Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- The Onco-Nephrology Field: The Role of Personalized Chemotherapy to Prevent Kidney Damage.Cancers · 2023Review
- Onconephrology 2022: An Update.Kidney360 · 2023Review
- Case report: Successful treatment of a patient undergoing haemodialysis with multifocal hepatocellular carcinoma using atezolizumab and bevacizumab.Frontiers in oncology · 2023Article
- Pegylated Liposomal Doxorubicin and Kidney-Limited Thrombotic Microangiopathy in a Kidney Transplant Recipient: A Case Report.Kidney medicine · 2022Article
- Treatment of acute kidney injury in cancer patients.Clinical kidney journal · 2022Review
- Lenvatinib-related renal microangiopathy: a case series.Virchows Archiv : an international journal of pathology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of novel targeted anticancer agents has led to overall improvement in the prognosis of many patients affected by various malignancies, but has also been associated with an increased risk of poorly characterized toxic effects to different organs, including the kidneys. The high prevalence of kidney impairment in the general population complicates the issue further. Nephrologists most frequently work with patients with cancer when they are asked to investigate kidney function to assess the need for dose adjustments in anticancer therapy. A thorough knowledge of the renal safety profile of novel life-prolonging anticancer therapies, specific features of their metabolism, and pharmacokinetic and pharmacodynamic properties (under normal circumstances as well as in the setting of renal replacement therapy) is, therefore, necessary to preserve kidney function as far as possible and to ensure optimum treatment. In this Review we summarize the present knowledge of renal toxic effects from novel targeted anticancer agents and discuss whether the management of patients' treatment needs to be modified. We also advocate the development of a new onconephrology subspeciality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.